文献速递神经免疫

儿童与成人自身免疫性脑炎免疫治疗对复发率影响的生存分析

Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis.
PubMed 文献 · Neurology · 2023-11-27

该回顾性研究纳入2007年1月至2021年11月在加州大学圣地亚哥分校和拉迪儿童医院就诊的符合 published 临床标准的自身免疫性脑炎患者,共30例儿童和75例成人。采用生存分析和Cox多变量回归模型,以利妥昔单抗暴露为时间依赖变量评估复发风险,发现利妥昔单抗使用与首次复发风险降低相关(合并数据HR 0.29,95%CI 0.09-0.85),尤其在成人中。

要点

  • 利妥昔单抗使用与AE患者首次复发风险降低相关(HR 0.29,95%CI 0.09-0.85)。
  • 儿童抗体阳性AE复发率31%,成人抗体阳性40%,成人抗体阴性20%。
  • 利妥昔单抗是AE最常用的二线免疫治疗。

核心结论

  • 在儿童和成人AE患者中复发常见,但抗NMDARE复发频率较低。
  • 采用严格的生存模型显示,利妥昔单抗使用对降低AE复发率有显著益处,尤其是在成人群体中。
  • 本研究提供IV级证据表明利妥昔单抗与AE患者较低的复发风险相关。

研究设计与样本

  • 回顾性研究,纳入2007年1月至2021年11月在加州大学圣地亚哥分校和拉迪儿童医院连续评估的符合 published 临床标准的AE患者。
  • 共筛查204例儿童和380例成人参与者,最终纳入30例儿童和75例成人。
  • 使用生存分析和Cox多变量回归模型,以利妥昔单抗暴露为时间依赖变量评估复发风险,进行合并和年龄分层分析。

主要发现

  • 最常见的抗体亚型在两组中均为抗NMDA受体(儿童76%,成人34%)。
  • 复发发生于31%的儿童抗体阳性、40%的成人抗体阳性和20%的成人抗体阴性病例。
  • 首次复发时间(TTFR)为:儿童抗体阳性10.6 ± 7.4个月,成人抗体阳性13.1 ± 24.5个月,成人抗体阴性6.9 ± 3.8个月。
  • 合并儿童和成人数据,利妥昔单抗使用与首次复发风险降低71%相关(HR 0.29,95%CI 0.09-0.85),与复发性复发风险降低51%相关(HR 0.49,95%CI 0.9-1.26)。
  • 儿童中利妥昔单抗使用的TTFR HR为0.30(95%CI 0.05-1.69),成人中为0.29(95%CI 0.07-1.29),非NMDA抗体阳性脑炎中为0.32(95%CI 0.07-1.39),抗NMDAR中为0.42(95%CI 0.07-2.67)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Prior observational studies for autoimmune encephalitis (AE) have mostly focused on outcomes after acute immunotherapies with better outcomes associated with earlier immunotherapy use. However, the impact of long-term immunotherapy and its association with clinical relapse is not well known. METHODS: We conducted a retrospective study of consecutive patients meeting published clinical criteria for AE evaluated at UC San Diego and Rady Children's Hospital from January 2007 to November 2021. Survival analysis and Cox multivariable regression models were used to evaluate relapse risk using rituximab exposure as a time-dependent variable. Pooled and age-stratified analyses were performed. RESULTS: A total of 204 pediatric and 380 adult participants were screened of which 30 pediatric and 75 adult participants were included. The most common antibody subtype in both cohorts was anti-NMDA receptor (76% in pediatric, 34% in adult). Relapses occurred in 31% of pediatric antibody-positive, 40% of adult antibody-positive, and 20% of adult antibody-negative cases. Times to first relapse (TTFR) were 10.6 ± 7.4 months (pediatric antibody-positive), 13.1 ± 24.5 months (adult antibody-positive), and 6.9 ± 3.8 months (adult antibody-negative). Rituximab was the most common second-line immunotherapy used. Combining pediatric and adult data, rituximab use was associated with a 71% lower hazard for time to first relapse (hazard ratio [HR] 0.29, 95% CI 0.09-0.85) and 51% lower hazard for recurring relapses (HR 0.49, 95% CI 0.9-1.26). The HR for TTFR with rituximab use in children was 0.30 (95% CI 0.05-1.69), 0.29 (95% CI 0.07-1.29) in adults, 0.32 in non-NMDA antibody-positive encephalitis (95% CI 0.07-1.39), and 0.42 (95% CI 0.07-2.67) for anti-NMDAR. DISCUSSION: Relapses are common in pediatric and adult patients with AE, although less frequently in anti-NMDARE. Using a rigorous survival model, we demonstrate a substantial benefit of rituximab use for reducing relapse rates in AE, especially for the adult population. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that rituximab is associated with a lower hazard to relapse in patients with AE.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Yang JH, Liu EN, Nguyen L, et al. Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis. Neurology. 2023. PMID: 37827848. doi:10.1212/WNL.0000000000207746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。